Sign in
av/unicycive-therapeutics--big.svg

NASDAQ:UNCY

Unicycive Therapeutics, Inc.

  • Stock

USD

Last Close

0.44

26/07 20:00

Market Cap

41.21M

Beta: -

Volume Today

1.87M

Avg: 6.05M

PE Ratio

−0.84

PFCF: −1.74

OverviewFinancialsFilingspeopleOwnershipAPIChartData

  • locale

    usUnited States

  • market

    STOCKS

  • industry

    Biotechnology

  • website

    www.unicycive.com

  • ipo date

    Jul 12, 2021

Unicycive Therapeutics, Inc., a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease; and UNI 494, for treatment of acute kidney injury. The company was incorporated in 2016 and is based in Los Altos, California.

Excel Tearsheet

peer of

Earnings

Earnings Release in 16 days

Earnings per Share (Estimate*)

-0.4-0.3-0.2-0.10.10.22020-03-312020-12-312021-11-112022-08-152023-05-162024-03-29

Revenue (Estimate*)

200K400K600K800K1M2020-03-312020-12-312021-11-112022-08-152023-05-162024-03-29

*Estimate based on analyst consensus